

CLAIMS

1. Glycoconjugates formed by the non-covalent association of polysaccharides with polypeptides characterized because the polysaccharide fraction has a molecular weight between 50 and 250 DKa, supporting phosphate functional groups in range 1 of these phosphate groups by between 5 and 25 residues of monosaccharide, with 40% mannose, and the rest can be either glucose and/or galactose, making up the main skeleton integrated by 1-6 bonds with 1-2 branches not higher than 60%; the polypeptide fraction is characterized by comprising a consensus sequence determined by $Z_{3-48}CZ_{9-13} C(Q,E,R,K) Z(Z_{\text{hydrophobic}}) (LIVM) Z_{15-39} CC(Z_{\text{hydrophilic}}) (Q,E,H) (L,V) Z_6 CZC Z_2 (L,I) Z_{13-56} G Z_{15-26} CZ(V,I,L,M) Z_{1-8} CZ_{1-12}$, where the symbols represent amino acids and the parenthesis indicate the preferential order, and being Z_n whatever n-amino acids.

2. Glycoconjugates, according to the above claim, characterized by the polypeptide fraction being made up by one or two polypeptides, as long as the mol/mol relation between the two polypeptides is between 1/3 and 3/1.

3. Glycocojugates, according to the first claim, characterized because the polypeptide fraction is a dimer having a molecular weight of 12 ± 0.5 KDa with amino acid sequences selected between:

Minor :

ESKGEREGSSSQCRQEVQRKDLSSCERYLRQSSRR
PSQQGCRGQIQEQQLRQCQEYIKQQVSGQGPRR

Major :

QQQESQQLQCCNQVKQVRDECQCEAIKYIAEDQIQGQLHGEESEVAQRAGEIVS
SCGVRCMRQTR
QERSLRGCCDHLKQMQSQCRCEGLRQAIEQQQSQGLQGLQDVFEAFRTAANLPSMCG

VSPTECRF

and in which the specific amino acids of the consensus sequence are indicated by underlining.

5 4. Glycoconjugates, according to the first claim,
characterized because the structural polypeptide fraction
is stabilized by disulphur or dimethylene bridges, and
can be oligomeric or preferably dimeric, and in this case
10 having at least two disulphur or dimethylene
intercatenary bridges.

528/ 09913351-081301
15 5. Glycoconjugates, according to the first claim,
with pharmacological activity and its application in
medicine for the treatment of disorders of the
immunological system.

6. Glycoconjugates according to the first claim and
its application in pharmacy for its use in the
preparation of usual galenical forms.

ADD
A2